{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:18:27Z","timestamp":1792811907434,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Universiti Putra Malaysia through the Institutional Grant Scheme","award":["(Grant No. GP-IPM\/2021\/9700000)"],"award-info":[{"award-number":["(Grant No. GP-IPM\/2021\/9700000)"]}],"id":[{"id":"https:\/\/ror.org\/02e91jd64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-13034-9","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:10:29Z","timestamp":1792750229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cannabidiol in Alzheimer\u2019s disease: evidence-weighted molecular mechanisms and translational challenges"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-3634","authenticated-orcid":false,"given":"Sreenivasulu","family":"Sura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-7363","authenticated-orcid":false,"given":"Saravanan","family":"Jagadeesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-2935","authenticated-orcid":false,"given":"Siti Saleha","family":"Masrudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-129X","authenticated-orcid":false,"given":"Mohamad Aris Mohd","family":"Moklas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8136-5604","authenticated-orcid":false,"given":"Nurul Huda Mohd","family":"Nor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"13034_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","unstructured":"GBD 2019 Dementia Forecasting Collaborators (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7:e105\u2013e125. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8","journal-title":"Lancet Public Health"},{"key":"13034_CR2","doi-asserted-by":"publisher","first-page":"e70235","DOI":"10.1002\/alz.70235","volume":"21","author":"Alzheimer\u2019s Association","year":"2025","unstructured":"Alzheimer\u2019s Association (2025) 2025 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 21:e70235. https:\/\/doi.org\/10.1002\/alz.70235","journal-title":"Alzheimers Dement"},{"key":"13034_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS (2014) Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505\u2013508. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5847","journal-title":"JAMA Neurol"},{"key":"13034_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8:595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210","journal-title":"EMBO Mol Med"},{"key":"13034_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","volume":"24","author":"CG Parsons","year":"2013","unstructured":"Parsons CG, Danysz W, Dekundy A, Pulte I (2013) Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease. Neurotox Res 24:358\u2013369. https:\/\/doi.org\/10.1007\/s12640-013-9398-z","journal-title":"Neurotox Res"},{"key":"13034_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"13034_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"issue":"3","key":"13034_CR8","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.26538\/tjnpr\/v10i3.39","volume":"10","author":"S Sura","year":"2026","unstructured":"Sura S, Vishnumukkala T, Okwuofu EO, Gopalakrishna PK, Jagadeesan S, Dandala KCR, Aris MM, Masrudin SS, Huda MN (2026) Cannabidiol from Cannabis sativa: a potential therapeutic agent for neurodegenerative diseases. Trop J Nat Prod Res 10(3):7933\u20137944. https:\/\/doi.org\/10.26538\/tjnpr\/v10i3.39","journal-title":"Trop J Nat Prod Res"},{"key":"13034_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13195-025-01756-0","volume":"17","author":"I Ra\u00efch","year":"2025","unstructured":"Ra\u00efch I, Lillo J, Rebassa JB, Gri\u00f1\u00e1n-Ferr\u00e9 C, Bellver-Sanchis A, Reyes-Resina I, Franco R, Pall\u00e0s M, Navarro G (2025) Cannabidiol as a multifaceted therapeutic agent: mitigating Alzheimer\u2019s disease pathology and enhancing cognitive function. Alzheimers Res Ther 17:109. https:\/\/doi.org\/10.1186\/s13195-025-01756-0","journal-title":"Alzheimers Res Ther"},{"key":"13034_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"K Iffland","year":"2017","unstructured":"Iffland K, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2:139\u2013154. https:\/\/doi.org\/10.1089\/can.2016.0034","journal-title":"Cannabis Cannabinoid Res"},{"key":"13034_CR11","doi-asserted-by":"publisher","first-page":"e28668","DOI":"10.1371\/journal.pone.0028668","volume":"6","author":"G Esposito","year":"2011","unstructured":"Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D, Cipriano M, Carrat\u00f9 MR, Iuvone T, Steardo L (2011) Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement. PLoS ONE 6:e28668. https:\/\/doi.org\/10.1371\/journal.pone.0028668","journal-title":"PLoS ONE"},{"key":"13034_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/biom14050564","volume":"14","author":"D Jantas","year":"2024","unstructured":"Jantas D, Le\u015bkiewicz M, Regulska M, Procner M, Warszy\u0144ski P, Laso\u0144 W (2024) Protective effects of cannabidiol (CBD) against oxidative stress, but not excitotoxic-related neuronal cell damage\u2014an in vitro study. Biomolecules 14:564. https:\/\/doi.org\/10.3390\/biom14050564","journal-title":"Biomolecules"},{"key":"13034_CR13","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41386-025-02213-0","volume":"50","author":"RS Toledano","year":"2025","unstructured":"Toledano RS, Akirav I (2025) Cannabidiol prevents cognitive and social deficits in a male rat model of Alzheimer\u2019s disease through CB1 activation and inflammation modulation. Neuropsychopharmacology 50:1916\u20131927. https:\/\/doi.org\/10.1038\/s41386-025-02213-0","journal-title":"Neuropsychopharmacology"},{"key":"13034_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11011-026-01894-w","volume":"41","author":"S Sura","year":"2026","unstructured":"Sura S, Jagadeesan S, Okwuofu EO, Dandala KCR, Ramakrishnappa S, Masrudin SSB, Moklas MAM, Judson JP, Fu GQ, Mohd Nor NH (2026) Cannabidiol attenuates tau hyperphosphorylation and cognitive deficits in an experimental model of Alzheimer\u2019s disease and is associated with restoration of PP2A expression. Metab Brain Dis 41:124. https:\/\/doi.org\/10.1007\/s11011-026-01894-w","journal-title":"Metab Brain Dis"},{"key":"13034_CR15","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1038\/s41380-026-03525-3","volume":"31","author":"J Liu","year":"2026","unstructured":"Liu J, Peng F, Li P, Yao C, Jin S, Wu G, Zhang T, Liang Q, Wang X, Du X (2026) Mechanistic insights into cannabidiol-mediated TrkB activation via FRS2 interaction in attenuating Alzheimer\u2019s disease pathology and cognitive impairment. Mol Psychiatry 31:4096\u20134112. https:\/\/doi.org\/10.1038\/s41380-026-03525-3","journal-title":"Mol Psychiatry"},{"key":"13034_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejphar.2009.03.010","volume":"612","author":"SE O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA (2009) Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612:61\u201368. https:\/\/doi.org\/10.1016\/j.ejphar.2009.03.010","journal-title":"Eur J Pharmacol"},{"key":"13034_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/bph.13368","volume":"173","author":"WH Hind","year":"2016","unstructured":"Hind WH, England TJ, O\u2019Sullivan SE (2016) Cannabidiol protects an in vitro model of the blood\u2013brain barrier from oxygen-glucose deprivation via PPAR\u03b3 and 5-HT1A receptors. Br J Pharmacol 173:815\u2013825. https:\/\/doi.org\/10.1111\/bph.13368","journal-title":"Br J Pharmacol"},{"key":"13034_CR18","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.3390\/molecules28073271","volume":"28","author":"J Castillo-Arellano","year":"2023","unstructured":"Castillo-Arellano J, Canseco-Alba A, Cutler SJ, Le\u00f3n F (2023) The polypharmacological effects of cannabidiol. Molecules 28:3271. https:\/\/doi.org\/10.3390\/molecules28073271","journal-title":"Molecules"},{"key":"13034_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/pharmaceutics12030265","volume":"12","author":"F Calapai","year":"2020","unstructured":"Calapai F, Cardia L, Sorbara EE, Navarra M, Gangemi S, Calapai G, Mannucci C (2020) Cannabinoids, blood-brain barrier, and brain disposition. Pharmaceutics 12:265. https:\/\/doi.org\/10.3390\/pharmaceutics12030265","journal-title":"Pharmaceutics"},{"key":"13034_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/pharmaceutics17020236","volume":"17","author":"M Lacerda","year":"2025","unstructured":"Lacerda M, Carona A, Castanheira S, Falc\u00e3o A, Bicker J, Fortuna A (2025) Pharmacokinetics of non-psychotropic phytocannabinoids. Pharmaceutics 17:236. https:\/\/doi.org\/10.3390\/pharmaceutics17020236","journal-title":"Pharmaceutics"},{"key":"13034_CR21","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","volume":"9","author":"SA Millar","year":"2018","unstructured":"Millar SA, Stone NL, Yates AS, O\u2019Sullivan SE (2018) A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol 9:1365. https:\/\/doi.org\/10.3389\/fphar.2018.01365","journal-title":"Front Pharmacol"},{"key":"13034_CR22","doi-asserted-by":"publisher","first-page":"105316","DOI":"10.1016\/j.jddst.2023.105316","volume":"92","author":"A Sitovs","year":"2024","unstructured":"Sitovs A, Logviss K, Lauberte L, Mohylyuk V (2024) Oral delivery of cannabidiol: revealing the formulation and absorption challenges. J Drug Deliv Sci Technol 92:105316. https:\/\/doi.org\/10.1016\/j.jddst.2023.105316","journal-title":"J Drug Deliv Sci Technol"},{"key":"13034_CR23","doi-asserted-by":"publisher","first-page":"1833021","DOI":"10.3389\/fnbeh.2026.1833021","volume":"20","author":"M Komedera","year":"2026","unstructured":"Komedera M, Wojda U, Kiryk A (2026) Cannabinoids in Alzheimer\u2019s disease: animal\u2013human evidence and clinical pharmacology challenges. Front Behav Neurosci 20:1833021. https:\/\/doi.org\/10.3389\/fnbeh.2026.1833021","journal-title":"Front Behav Neurosci"},{"key":"13034_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2174\/1871527316666170303144817","volume":"16","author":"F Caraci","year":"2017","unstructured":"Caraci F, Sultana J, Drago F, Spina E (2017) Clinically relevant drug interactions with anti-Alzheimer\u2019s drugs. CNS Neurol Disord Drug Targets 16:501\u2013513. https:\/\/doi.org\/10.2174\/1871527316666170303144817","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"13034_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40263-026-01280-1","volume":"40","author":"I Bendik","year":"2026","unstructured":"Bendik I, Beck M, Manderna A, Roos FF, Wang J, McCarthy D et al (2026) Comparative pharmacokinetics and safety of cannabidiol in a powder formulation, CBtru\u00ae, vs an oil-based formulation, Epidyolex\u00ae, under fasted and fed conditions in healthy participants: a randomized open-label cross-over phase I study. CNS Drugs 40:709\u2013723. https:\/\/doi.org\/10.1007\/s40263-026-01280-1","journal-title":"CNS Drugs"},{"key":"13034_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","volume":"134","author":"T Bisogno","year":"2001","unstructured":"Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845\u2013852. https:\/\/doi.org\/10.1038\/sj.bjp.0704327","journal-title":"Br J Pharmacol"},{"key":"13034_CR27","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790\u20134805. https:\/\/doi.org\/10.1111\/bph.13250","journal-title":"Br J Pharmacol"},{"key":"13034_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/bs.apha.2017.03.007","volume":"80","author":"AC Howlett","year":"2017","unstructured":"Howlett AC, Abood ME (2017) CB1 and CB2 receptor pharmacology. Adv Pharmacol 80:169\u2013206. https:\/\/doi.org\/10.1016\/bs.apha.2017.03.007","journal-title":"Adv Pharmacol"},{"key":"13034_CR29","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","volume":"290","author":"MW Elmes","year":"2015","unstructured":"Elmes MW, Kaczocha M, Berger WT, Leung KN, Ralph BP, Wang L, Sweeney JM, Miyauchi JT, Tsirka SE, Ojima I, Deutsch DG (2015) Fatty acid-binding proteins are intracellular carriers for \u22069-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem 290:8711\u20138721. https:\/\/doi.org\/10.1074\/jbc.M114.618447","journal-title":"J Biol Chem"},{"key":"13034_CR30","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.1073\/pnas.0511232103","volume":"103","author":"EJ Carrier","year":"2006","unstructured":"Carrier EJ, Auchampach JA, Hillard CJ (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 103:7895\u20137900. https:\/\/doi.org\/10.1073\/pnas.0511232103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13034_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.tips.2024.12.005","volume":"46","author":"OJ Manzoni","year":"2025","unstructured":"Manzoni OJ, Manduca A, Trezza V (2025) Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders. Trends Pharmacol Sci 46:145\u2013162. https:\/\/doi.org\/10.1016\/j.tips.2024.12.005","journal-title":"Trends Pharmacol Sci"},{"key":"13034_CR32","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","volume":"163","author":"L De Petrocellis","year":"2011","unstructured":"De Petrocellis L, Ligresti A, Moriello AS, Allar\u00e0 M, Bisogno T, Petrosino S, Stott CG, Di Marzo V (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163:1479\u20131494. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01166.x","journal-title":"Br J Pharmacol"},{"key":"13034_CR33","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","volume":"152","author":"E Ryberg","year":"2007","unstructured":"Ryberg E, Larsson N, Sj\u00f6gren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092\u20131101. https:\/\/doi.org\/10.1038\/sj.bjp.0707460","journal-title":"Br J Pharmacol"},{"key":"13034_CR34","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ptr.5095","volume":"28","author":"C Scuderi","year":"2014","unstructured":"Scuderi C, Steardo L, Esposito G (2014) Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPAR\u03b3 involvement. Phytother Res 28:1007\u20131013. https:\/\/doi.org\/10.1002\/ptr.5095","journal-title":"Phytother Res"},{"key":"13034_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3233\/JAD-131961","volume":"42","author":"N Maroof","year":"2014","unstructured":"Maroof N, Ravipati S, Pardon MC, Barrett DA, Kendall DA (2014) Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the A\u03b2PPswe\/PS1\u2206E9 mouse model of Alzheimer\u2019s disease. J Alzheimers Dis 42:227\u2013245. https:\/\/doi.org\/10.3233\/JAD-131961","journal-title":"J Alzheimers Dis"},{"key":"13034_CR36","doi-asserted-by":"publisher","first-page":"38543","DOI":"10.1074\/jbc.M110.162040","volume":"285","author":"J Noonan","year":"2010","unstructured":"Noonan J, Tanveer R, Klompas A, Gowran A, McKiernan J, Campbell VA (2010) Endocannabinoids prevent \u03b2-amyloid-mediated lysosomal destabilization in cultured neurons. J Biol Chem 285:38543\u201338554. https:\/\/doi.org\/10.1074\/jbc.M110.162040","journal-title":"J Biol Chem"},{"key":"13034_CR37","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3233\/JAD-141014","volume":"43","author":"E Aso","year":"2015","unstructured":"Aso E, S\u00e1nchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I (2015) Cannabis-based medicine reduces multiple pathological processes in A\u03b2PP\/PS1 mice. J Alzheimers Dis 43:977\u2013991. https:\/\/doi.org\/10.3233\/JAD-141014","journal-title":"J Alzheimers Dis"},{"key":"13034_CR38","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3233\/JAD-160533","volume":"54","author":"E Aso","year":"2016","unstructured":"Aso E, Andr\u00e9s-Benito P, Ferrer I (2016) Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model. J Alzheimers Dis 54:903\u2013912. https:\/\/doi.org\/10.3233\/JAD-160533","journal-title":"J Alzheimers Dis"},{"key":"13034_CR39","doi-asserted-by":"publisher","first-page":"118902","DOI":"10.1016\/j.biopha.2025.118902","volume":"194","author":"S Ruiz de Mart\u00edn Esteban","year":"2026","unstructured":"Ruiz de Mart\u00edn Esteban S, Grande MT, Mart\u00ednez-Relimpio AM, Herr\u00e1ez-Aguilar D, Mostany R, Hillard CJ, Hind WH, Romero J (2026) Treatment with a botanical mixture of cannabidiol:\u22069-tetrahydrocannabinol enhances microglial phagocytosis and shapes amyloid plaques in a mouse model of Alzheimer\u2019s disease. Biomed Pharmacother 194:118902. https:\/\/doi.org\/10.1016\/j.biopha.2025.118902","journal-title":"Biomed Pharmacother"},{"key":"13034_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neurobiolaging.2026.04.003","volume":"164","author":"M Coles","year":"2026","unstructured":"Coles M, Rosa Porto R, Chesworth R, Steiner-Lim GZ, Karl T (2026) Combining cannabidiol and delta-9-tetrahydrocannabinol at a 50:3 ratio \u2013 a new therapeutic strategy for APPSwe\/PS1\u2206E9 transgenic mice? Neurobiol Aging 164:79\u201390. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2026.04.003","journal-title":"Neurobiol Aging"},{"key":"13034_CR41","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1089\/can.2023.0101","volume":"9","author":"MA Arnanz","year":"2024","unstructured":"Arnanz MA, Ruiz de Mart\u00edn Esteban S, Mart\u00ednez Relimpio AM, Rimmerman N, Tweezer Zaks N, Grande MT, Romero J (2024) Effects of chronic, low-dose cannabinoids, cannabidiol, delta-9-tetrahydrocannabinol and a combination of both, on amyloid pathology in the 5xFAD mouse model of Alzheimer\u2019s disease. Cannabis Cannabinoid Res 9:1312\u20131325. https:\/\/doi.org\/10.1089\/can.2023.0101","journal-title":"Cannabis Cannabinoid Res"},{"key":"13034_CR42","doi-asserted-by":"publisher","first-page":"174101","DOI":"10.1016\/j.pbb.2025.174101","volume":"257","author":"B Aumer","year":"2025","unstructured":"Aumer B, Rosa Porto R, Coles M, Ulmer N, Watt G, Kielstein H, Karl T (2025) Combination treatment with medium dose THC and CBD had no therapeutic effect in a transgenic mouse model for Alzheimer\u2019s disease but affected other domains including anxiety-related behaviours and object recognition memory. Pharmacol Biochem Behav 257:174101. https:\/\/doi.org\/10.1016\/j.pbb.2025.174101","journal-title":"Pharmacol Biochem Behav"},{"key":"13034_CR43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ptr.8369","volume":"39","author":"RM Vitale","year":"2025","unstructured":"Vitale RM, Morace AM, D\u2019Errico A, Ricciardi F, Fusco A, Boccella S, Guida F, Nasso R, Rading S, Karsak M, Caprioglio D, Iannotti FA, Arcone R, Luongo L, Masullo M, Maione S, Amodeo P (2025) Identification of cannabidiolic and cannabigerolic acids as MTDL AChE, BuChE, and BACE-1 inhibitors against Alzheimer\u2019s disease by in silico, in vitro, and in vivo studies. Phytother Res 39:233\u2013245. https:\/\/doi.org\/10.1002\/ptr.8369","journal-title":"Phytother Res"},{"key":"13034_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1471-4159.2003.02327.x","volume":"89","author":"T Iuvone","year":"2004","unstructured":"Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 89:134\u2013141. https:\/\/doi.org\/10.1111\/j.1471-4159.2003.02327.x","journal-title":"J Neurochem"},{"key":"13034_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10571-013-9984-x","volume":"34","author":"E Janefjord","year":"2014","unstructured":"Janefjord E, M\u00e5\u00e5g JLV, Harvey BS, Smid SD (2014) Cannabinoid effects on \u03b2 amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell Mol Neurobiol 34:31\u201342. https:\/\/doi.org\/10.1007\/s10571-013-9984-x","journal-title":"Cell Mol Neurobiol"},{"key":"13034_CR46","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1124\/mol.111.071290","volume":"79","author":"AM Mart\u00edn-Moreno","year":"2011","unstructured":"Mart\u00edn-Moreno AM, Reigada D, Ram\u00edrez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer\u2019s disease. Mol Pharmacol 79:964\u2013973. https:\/\/doi.org\/10.1124\/mol.111.071290","journal-title":"Mol Pharmacol"},{"key":"13034_CR47","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/bph.13497","volume":"173","author":"SE O\u2019Sullivan","year":"2016","unstructured":"O\u2019Sullivan SE (2016) An update on PPAR activation by cannabinoids. Br J Pharmacol 173:1899\u20131910. https:\/\/doi.org\/10.1111\/bph.13497","journal-title":"Br J Pharmacol"},{"key":"13034_CR48","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3233\/JAD-140921","volume":"42","author":"D Cheng","year":"2014","unstructured":"Cheng D, Spiro AS, Jenner AM, Garner B, Karl T (2014) Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer\u2019s disease transgenic mice. J Alzheimers Dis 42:1383\u20131396. https:\/\/doi.org\/10.3233\/JAD-140921","journal-title":"J Alzheimers Dis"},{"key":"13034_CR49","doi-asserted-by":"publisher","first-page":"587604","DOI":"10.3389\/fphar.2020.587604","volume":"11","author":"M Coles","year":"2020","unstructured":"Coles M, Watt G, Kreilaus F, Karl T (2020) Medium-dose chronic cannabidiol treatment reverses object recognition memory deficits of APPswe\/PS1\u2206E9 transgenic female mice. Front Pharmacol 11:587604. https:\/\/doi.org\/10.3389\/fphar.2020.587604","journal-title":"Front Pharmacol"},{"key":"13034_CR50","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3233\/JAD-191242","volume":"74","author":"G Watt","year":"2020","unstructured":"Watt G, Shang K, Zieba J, Olaya J, Li H, Garner B, Karl T (2020) Chronic treatment with 50\u00a0mg\/kg cannabidiol improves cognition and moderately reduces A\u03b240 levels in 12-month-old male A\u03b2PPswe\/PS1\u2206E9 transgenic mice. J Alzheimers Dis 74:937\u2013950. https:\/\/doi.org\/10.3233\/JAD-191242","journal-title":"J Alzheimers Dis"},{"key":"13034_CR51","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/ph19030374","volume":"19","author":"G Watt","year":"2026","unstructured":"Watt G, Olaya J, Muench G, Garner B, Karl T (2026) Effects of chronic 100\u00a0mg\/kg cannabidiol treatment in male double transgenic APPswe\/PS1\u2206E9 mice. Pharmaceuticals 19:374. https:\/\/doi.org\/10.3390\/ph19030374","journal-title":"Pharmaceuticals"},{"key":"13034_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E (2016) Tau in physiology and pathology. Nat Rev Neurosci 17:22\u201335. https:\/\/doi.org\/10.1038\/nrn.2015.1","journal-title":"Nat Rev Neurosci"},{"key":"13034_CR53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00109-005-0025-1","volume":"84","author":"G Esposito","year":"2006","unstructured":"Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T (2006) The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt\/beta-catenin pathway rescue in PC12 cells. J Mol Med (Berl) 84:253\u2013258. https:\/\/doi.org\/10.1007\/s00109-005-0025-1","journal-title":"J Mol Med (Berl)"},{"key":"13034_CR54","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.3390\/cells10123521","volume":"10","author":"S Alali","year":"2021","unstructured":"Alali S, Riazi G, Ashrafi-Kooshk MR, Meknatkhah S, Ahmadian S, Hooshyari Ardakani M, Hosseinkhani B (2021) Cannabidiol inhibits tau aggregation in vitro. Cells 10:3521. https:\/\/doi.org\/10.3390\/cells10123521","journal-title":"Cells"},{"key":"13034_CR55","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1007\/s11033-026-12578-0","volume":"53","author":"S Sura","year":"2026","unstructured":"Sura S, Jagadeesan S, Mohd Moklas MA, Masrudin SS, Dandala KCR, Judson JP, MohdNor NH (2026) Tau dysfunction in Alzheimer\u2019s disease: molecular and cellular mechanisms, genetic modulation, and therapeutic perspectives. Mol Biol Rep 53:1396. https:\/\/doi.org\/10.1007\/s11033-026-12578-0","journal-title":"Mol Biol Rep"},{"key":"13034_CR56","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/abbs\/gmx073","volume":"49","author":"A Vall\u00e9e","year":"2017","unstructured":"Vall\u00e9e A, Lecarpentier Y, Guillevin R, Vall\u00e9e JN (2017) Effects of cannabidiol interactions with Wnt\/\u03b2-catenin pathway and PPAR\u03b3 on oxidative stress and neuroinflammation in Alzheimer\u2019s disease. Acta Biochim Biophys Sin (Shanghai) 49:853\u2013866. https:\/\/doi.org\/10.1093\/abbs\/gmx073","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"13034_CR57","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1177\/13872877261421654","volume":"110","author":"AG Nixon","year":"2026","unstructured":"Nixon AG, Hong NS, Mirza Agha B, Ham JR, Monteith M, Kaloa T, Kyriazopolus A, Nielsen M, Robertson DR, Golubov A, Sutherland RJ, Kovalchuk I, Iwaniuk AN, Mohajerani MH, McDonald RJ (2026) The effects of chronic cannabidiol administration on brain pathology and behavioral deficits found in the tau P301S-line PS19 mouse model of Alzheimer\u2019s disease. J Alzheimers Dis 110:1099\u20131126. https:\/\/doi.org\/10.1177\/13872877261421654","journal-title":"J Alzheimers Dis"},{"key":"13034_CR58","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JCS, Cole GM, Golenbock DT, Kummer MP (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14:388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"key":"13034_CR59","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00401-015-1513-1","volume":"131","author":"M Pekny","year":"2016","unstructured":"Pekny M, Pekna M, Messing A, Steinh\u00e4user C, Lee JM, Parpura V, Hol EM, Sofroniew MV, Verkhratsky A (2016) Astrocytes: a central element in neurological diseases. Acta Neuropathol 131:323\u2013345. https:\/\/doi.org\/10.1007\/s00401-015-1513-1","journal-title":"Acta Neuropathol"},{"key":"13034_CR60","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","volume":"151","author":"G Esposito","year":"2007","unstructured":"Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V (2007) Cannabidiol in vivo blunts \u03b2-amyloid-induced neuroinflammation by suppressing IL-1\u03b2 and iNOS expression. Br J Pharmacol 151:1272\u20131279. https:\/\/doi.org\/10.1038\/sj.bjp.0707337","journal-title":"Br J Pharmacol"},{"key":"13034_CR61","doi-asserted-by":"publisher","first-page":"11963","DOI":"10.3390\/ijms262411963","volume":"26","author":"S Wu","year":"2025","unstructured":"Wu S, Rajiah T, Ali AB (2025) Therapeutic potential for cannabidiol on Alzheimer\u2019s disease-related neuroinflammation: a systematic review and meta-analysis. Int J Mol Sci 26:11963. https:\/\/doi.org\/10.3390\/ijms262411963","journal-title":"Int J Mol Sci"},{"key":"13034_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.neulet.2006.01.047","volume":"399","author":"G Esposito","year":"2006","unstructured":"Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T (2006) Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid-stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 399:91\u201395. https:\/\/doi.org\/10.1016\/j.neulet.2006.01.047","journal-title":"Neurosci Lett"},{"key":"13034_CR63","doi-asserted-by":"publisher","first-page":"118624","DOI":"10.1016\/j.lfs.2020.118624","volume":"264","author":"F Hao","year":"2021","unstructured":"Hao F, Feng Y (2021) Cannabidiol enhanced the hippocampal immune response and autophagy of APP\/PS1 Alzheimer\u2019s mice uncovered by RNA-seq. Life Sci 264:118624. https:\/\/doi.org\/10.1016\/j.lfs.2020.118624","journal-title":"Life Sci"},{"key":"13034_CR64","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","volume":"110","author":"RC Paolicelli","year":"2022","unstructured":"Paolicelli RC, Sierra A, Stevens B, Tremblay ME, Aguzzi A, Ajami B et al (2022) Microglia states and nomenclature: a field at its crossroads. Neuron 110:3458\u20133483. https:\/\/doi.org\/10.1016\/j.neuron.2022.10.020","journal-title":"Neuron"},{"key":"13034_CR65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10571-026-01671-4","volume":"46","author":"PK Gopalakrishna","year":"2026","unstructured":"Gopalakrishna PK, Che Mohd Nassir CMN, Anandan S, Hussan F, Dandala KCR, Sura S, Jagadeesan S, Mohd Moklas MA, Vishnumukkala T, Hein ZM (2026) The immuno-glial connectome in Alzheimer\u2019s disease: integrating central and peripheral inflammatory networks. Cell Mol Neurobiol 46:31. https:\/\/doi.org\/10.1007\/s10571-026-01671-4","journal-title":"Cell Mol Neurobiol"},{"key":"13034_CR66","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-9-8","volume":"9","author":"AM Mart\u00edn-Moreno","year":"2012","unstructured":"Mart\u00edn-Moreno AM, Brera B, Spuch C, Carro E, Garc\u00eda-Garc\u00eda L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML (2012) Prolonged oral cannabinoid administration prevents neuroinflammation, lowers \u03b2-amyloid levels and improves cognitive performance in Tg APP2576 mice. J Neuroinflammation 9:8. https:\/\/doi.org\/10.1186\/1742-2094-9-8","journal-title":"J Neuroinflammation"},{"key":"13034_CR67","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/jnen\/60.8.759","volume":"60","author":"A Nunomura","year":"2001","unstructured":"Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:759\u2013767. https:\/\/doi.org\/10.1093\/jnen\/60.8.759","journal-title":"J Neuropathol Exp Neurol"},{"key":"13034_CR68","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11033-023-09021-z","volume":"51","author":"R Dhapola","year":"2024","unstructured":"Dhapola R, Beura SK, Sharma P, Singh SK, HariKrishnaReddy D (2024) Oxidative stress in Alzheimer\u2019s disease: current knowledge of signaling pathways and therapeutics. Mol Biol Rep 51:48. https:\/\/doi.org\/10.1007\/s11033-023-09021-z","journal-title":"Mol Biol Rep"},{"key":"13034_CR69","doi-asserted-by":"publisher","first-page":"8268","DOI":"10.1073\/pnas.95.14.8268","volume":"95","author":"AJ Hampson","year":"1998","unstructured":"Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)\u22069-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95:8268\u20138273. https:\/\/doi.org\/10.1073\/pnas.95.14.8268","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13034_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antiox9010021","volume":"9","author":"S Atalay","year":"2020","unstructured":"Atalay S, Jarocka-Karpowicz I, Skrzydlewska E (2020) Antioxidative and anti-inflammatory properties of cannabidiol. Antioxid (Basel) 9:21. https:\/\/doi.org\/10.3390\/antiox9010021","journal-title":"Antioxid (Basel)"},{"key":"13034_CR71","doi-asserted-by":"publisher","first-page":"12663","DOI":"10.3390\/molecules181012663","volume":"18","author":"RS Borges","year":"2013","unstructured":"Borges RS, Batista J Jr, Viana RB, Baetas AC, Orestes E, Andrade MA, Hon\u00f3rio KM, Da Silva ABF (2013) Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants. Molecules 18:12663\u201312674. https:\/\/doi.org\/10.3390\/molecules181012663","journal-title":"Molecules"},{"key":"13034_CR72","doi-asserted-by":"publisher","first-page":"7907","DOI":"10.1038\/s41598-023-34924-z","volume":"13","author":"M Tripson","year":"2023","unstructured":"Tripson M, Litwa K, Soderstrom K (2023) Cannabidiol inhibits neuroinflammatory responses and circuit-associated synaptic loss following damage to a songbird vocal pre-motor cortical-like region. Sci Rep 13:7907. https:\/\/doi.org\/10.1038\/s41598-023-34924-z","journal-title":"Sci Rep"},{"key":"13034_CR73","doi-asserted-by":"publisher","first-page":"101321","DOI":"10.1016\/j.redox.2019.101321","volume":"28","author":"L Casares","year":"2020","unstructured":"Casares L, Garc\u00eda V, Garrido-Rodr\u00edguez M, Mill\u00e1n E, Collado JA, Garc\u00eda-Mart\u00edn A, Pe\u00f1arando J, Calzado MA, de la Vega L, Mu\u00f1oz E (2020) Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol 28:101321. https:\/\/doi.org\/10.1016\/j.redox.2019.101321","journal-title":"Redox Biol"},{"key":"13034_CR74","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1523\/JNEUROSCI.4212-08.2009","volume":"29","author":"D Ryan","year":"2009","unstructured":"Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B (2009) Cannabidiol targets mitochondria to regulate intracellular Ca2\u2009+\u2009levels. J Neurosci 29:2053\u20132063. https:\/\/doi.org\/10.1523\/JNEUROSCI.4212-08.2009","journal-title":"J Neurosci"},{"key":"13034_CR75","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1038\/s41380-024-02789-x","volume":"30","author":"J Jin","year":"2025","unstructured":"Jin J, Fu C, Xia J, Luo H, Wang X, Chen S, Mao H, Yuan K, Lu L, Xiong W, Zou G (2025) Cannabidiol ameliorates cognitive decline in 5\u00d7FAD mouse model of Alzheimer\u2019s disease through potentiating the function of extrasynaptic glycine receptors. Mol Psychiatry 30:1817\u20131827. https:\/\/doi.org\/10.1038\/s41380-024-02789-x First published online 12 October 2024","journal-title":"Mol Psychiatry"},{"key":"13034_CR76","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572\u2013580. https:\/\/doi.org\/10.1002\/ana.410300410","journal-title":"Ann Neurol"},{"key":"13034_CR77","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/JAD-2008-15112","volume":"15","author":"G Leuba","year":"2008","unstructured":"Leuba G, Savioz A, Vernay A, Carnal B, Kraftsik R, Tardif E, Riederer I, Riederer BM (2008) Differential changes in synaptic proteins in the Alzheimer frontal cortex with marked increase in PSD-95 postsynaptic protein. J Alzheimers Dis 15:139\u2013151. https:\/\/doi.org\/10.3233\/JAD-2008-15112","journal-title":"J Alzheimers Dis"},{"key":"13034_CR78","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11064-018-2513-z","volume":"44","author":"B Hughes","year":"2019","unstructured":"Hughes B, Herron CE (2019) Cannabidiol reverses deficits in hippocampal LTP in a model of Alzheimer\u2019s disease. Neurochem Res 44:703\u2013713. https:\/\/doi.org\/10.1007\/s11064-018-2513-z","journal-title":"Neurochem Res"},{"key":"13034_CR79","doi-asserted-by":"publisher","first-page":"e0296586","DOI":"10.1371\/journal.pone.0296586","volume":"20","author":"MN Goodland","year":"2025","unstructured":"Goodland MN, Banerjee S, Niehoff ML, Young BJ, Macarthur H, Butler AA, Morley JE, Farr SA (2025) Cannabidiol improves learning and memory deficits and alleviates anxiety in 12-month-old SAMP8 mice. PLoS ONE 20:e0296586. https:\/\/doi.org\/10.1371\/journal.pone.0296586","journal-title":"PLoS ONE"},{"key":"13034_CR80","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1017\/S1461145712001502","volume":"16","author":"AC Campos","year":"2013","unstructured":"Campos AC, Ortega Z, Palazuelos J, Foga\u00e7a MV, Aguiar DC, D\u00edaz-Alonso J, Ortega-Guti\u00e9rrez S, V\u00e1zquez-Villa H, Moreira FA, Guzm\u00e1n M, Galve-Roperh I, Guimar\u00e3es FS (2013) The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol 16:1407\u20131419. https:\/\/doi.org\/10.1017\/S1461145712001502","journal-title":"Int J Neuropsychopharmacol"},{"key":"13034_CR81","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fnbeh.2020.00109","volume":"14","author":"M\u00c1 Luj\u00e1n","year":"2020","unstructured":"Luj\u00e1n M\u00c1, Valverde O (2020) The pro-neurogenic effects of cannabidiol and its potential therapeutic implications in psychiatric disorders. Front Behav Neurosci 14:109. https:\/\/doi.org\/10.3389\/fnbeh.2020.00109","journal-title":"Front Behav Neurosci"},{"key":"13034_CR82","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.stem.2023.01.002","volume":"30","author":"E Salta","year":"2023","unstructured":"Salta E, Lazarov O, Fitzsimons CP, Tanzi R, Lucassen PJ, Choi SH (2023) Adult hippocampal neurogenesis in Alzheimer\u2019s disease: a roadmap to clinical relevance. Cell Stem Cell 30:120\u2013136. https:\/\/doi.org\/10.1016\/j.stem.2023.01.002","journal-title":"Cell Stem Cell"},{"key":"13034_CR83","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.bbadis.2013.09.010","volume":"1842","author":"RH Swerdlow","year":"2014","unstructured":"Swerdlow RH, Burns JM, Khan SM (2014) The Alzheimer\u2019s disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta 1842:1219\u20131231. https:\/\/doi.org\/10.1016\/j.bbadis.2013.09.010","journal-title":"Biochim Biophys Acta"},{"key":"13034_CR84","doi-asserted-by":"publisher","first-page":"617588","DOI":"10.3389\/fnagi.2021.617588","volume":"13","author":"A Misrani","year":"2021","unstructured":"Misrani A, Tabassum S, Yang L (2021) Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease. Front Aging Neurosci 13:617588. https:\/\/doi.org\/10.3389\/fnagi.2021.617588","journal-title":"Front Aging Neurosci"},{"key":"13034_CR85","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1590\/1516-4446-2012-0886","volume":"35","author":"SS Valvassori","year":"2013","unstructured":"Valvassori SS, Bavaresco DV, Scaini G, Varela RB, Streck EL, Chagas MH, Hallak JEC, Zuardi AW, Crippa JA, Quevedo J (2013) Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. Braz J Psychiatry 35:380\u2013386. https:\/\/doi.org\/10.1590\/1516-4446-2012-0886","journal-title":"Braz J Psychiatry"},{"key":"13034_CR86","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3390\/ijms23031076","volume":"23","author":"D de Paula Faria","year":"2022","unstructured":"de Paula Faria D, Estessi de Souza L, Duran FLS, Buchpiguel CA, Britto LR, Crippa JAS, Filho GB, Real CC (2022) Cannabidiol treatment improves glucose metabolism and memory in streptozotocin-induced Alzheimer\u2019s disease rat model: a proof-of-concept study. Int J Mol Sci 23:1076. https:\/\/doi.org\/10.3390\/ijms23031076","journal-title":"Int J Mol Sci"},{"key":"13034_CR87","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/can.2022.0011","volume":"8","author":"CD Drummond-Main","year":"2023","unstructured":"Drummond-Main CD, Ahn Y, Kesler M, Gavrilovici C, Kim DY, Kiroski I, Baglot SL, Chen A, Sharkey KA, Hill MN, Teskey GC, Rho JM (2023) Cannabidiol impairs brain mitochondrial metabolism and neuronal integrity. Cannabis Cannabinoid Res 8:283\u2013298. https:\/\/doi.org\/10.1089\/can.2022.0011","journal-title":"Cannabis Cannabinoid Res"},{"key":"13034_CR88","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1742-2094-9-115","volume":"9","author":"B Stansley","year":"2012","unstructured":"Stansley B, Post J, Hensley K (2012) A comparative review of cell culture systems for the study of microglial biology in Alzheimer\u2019s disease. J Neuroinflammation 9:115. https:\/\/doi.org\/10.1186\/1742-2094-9-115","journal-title":"J Neuroinflammation"},{"key":"13034_CR89","doi-asserted-by":"publisher","first-page":"e2462","DOI":"10.3791\/2462","volume":"48","author":"X Opitz-Araya","year":"2011","unstructured":"Opitz-Araya X, Barria A (2011) Organotypic hippocampal slice cultures. J Vis Exp 48:e2462. https:\/\/doi.org\/10.3791\/2462","journal-title":"J Vis Exp"},{"key":"13034_CR90","doi-asserted-by":"publisher","first-page":"785276","DOI":"10.3389\/fnins.2021.785276","volume":"15","author":"DI Javonillo","year":"2022","unstructured":"Javonillo DI, Tran KM, Phan J et al (2022) Systematic phenotyping and characterization of the 3xTg-AD mouse model of Alzheimer\u2019s disease. Front Neurosci 15:785276. https:\/\/doi.org\/10.3389\/fnins.2021.785276","journal-title":"Front Neurosci"},{"key":"13034_CR91","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.15252\/embj.201797397","volume":"36","author":"H Sasaguri","year":"2017","unstructured":"Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, Saido TC (2017) APP mouse models for Alzheimer\u2019s disease preclinical studies. EMBO J 36:2473\u20132487. https:\/\/doi.org\/10.15252\/embj.201797397","journal-title":"EMBO J"},{"key":"13034_CR92","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129\u201310140. https:\/\/doi.org\/10.1523\/JNEUROSCI.1202-06.2006","journal-title":"J Neurosci"},{"key":"13034_CR93","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s12035-015-9132-3","volume":"53","author":"P Grieb","year":"2016","unstructured":"Grieb P (2016) Intracerebroventricular streptozotocin injections as a model of Alzheimer\u2019s disease: in search of a relevant mechanism. Mol Neurobiol 53:1741\u20131752. https:\/\/doi.org\/10.1007\/s12035-015-9132-3","journal-title":"Mol Neurobiol"},{"key":"13034_CR94","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.exger.2005.05.007","volume":"40","author":"DA Butterfield","year":"2005","unstructured":"Butterfield DA, Poon HF (2005) The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer\u2019s disease. Exp Gerontol 40:774\u2013783. https:\/\/doi.org\/10.1016\/j.exger.2005.05.007","journal-title":"Exp Gerontol"},{"key":"13034_CR95","doi-asserted-by":"publisher","first-page":"20247","DOI":"10.1038\/s41598-022-24292-5","volume":"12","author":"A G\u00e1sp\u00e1r","year":"2022","unstructured":"G\u00e1sp\u00e1r A, Hutka B, Ernyey AJ, Tajti BT, Varga BT, Z\u00e1dori ZS et al (2022) Performance of the intracerebroventricularly injected streptozotocin Alzheimer\u2019s disease model in a translationally relevant, aged and experienced rat population. Sci Rep 12:20247. https:\/\/doi.org\/10.1038\/s41598-022-24292-5","journal-title":"Sci Rep"},{"key":"13034_CR96","doi-asserted-by":"publisher","unstructured":"Sura S, Vishnumukkala T, Masrudin SS, Mohd Moklas MA, Kamaruzzaman MA, Dandala KCR, Gandrakota R, Mohd Nor NH (2025) Therapeutic potential of cannabidiol in alleviating cognitive decline and hippocampal damage in a rat model of Alzheimer\u2019s disease. Malays J Sci 44(Special Issue 189\u201396. https:\/\/doi.org\/10.22452\/mjs.vol44sp1.14","DOI":"10.22452\/mjs.vol44sp1.14"},{"key":"13034_CR97","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/nprot.2006.116","volume":"1","author":"CV Vorhees","year":"2006","unstructured":"Vorhees CV, Williams MT (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1:848\u2013858. https:\/\/doi.org\/10.1038\/nprot.2006.116","journal-title":"Nat Protoc"},{"key":"13034_CR98","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","volume":"27","author":"N Herrmann","year":"2019","unstructured":"Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff NPLG, Kiss A, Black SE, Lanct\u00f4t KL (2019) Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease. Am J Geriatr Psychiatry 27:1161\u20131173. https:\/\/doi.org\/10.1016\/j.jagp.2019.05.002","journal-title":"Am J Geriatr Psychiatry"},{"key":"13034_CR99","doi-asserted-by":"publisher","first-page":"9449","DOI":"10.3390\/ijms23169449","volume":"23","author":"K Nitzan","year":"2022","unstructured":"Nitzan K, Ellenbogen L, Bentulila Z, David D, Franko M, Break EP, Zoharetz M, Shamir A, Sarne Y, Doron R (2022) An ultra-low dose of \u22069-tetrahydrocannabinol alleviates Alzheimer\u2019s disease-related cognitive impairments and modulates TrkB receptor expression in a 5XFAD mouse model. Int J Mol Sci 23:9449. https:\/\/doi.org\/10.3390\/ijms23169449","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-13034-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-13034-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-13034-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:03:38Z","timestamp":1792796618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-13034-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["13034"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-13034-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"6 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a narrative review based on previously published literature. The authors confirm that the manuscript is an original and independent scholarly synthesis prepared by the listed authors. No undisclosed third party, commercial manuscript agency or paper mill was involved in its preparation.","order":2,"name":"Ethics","label":"Disclosure statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1792"}}